

WHAT IS CLAIMED IS:

(024-US1)

1. An isolated polynucleotide comprising the sequence of any one of SEQ ID Nos: 1-48, 52-64, 66, 68-84, 86, 88-93, 101-131.

5

2. An isolated polynucleotide the expression of which is modulated in neural cells subjected to neurotoxic stress having the sequence of:

10

(a) any one of SEQ ID NOS: 1-131

(b) a naturally-occurring polynucleotide

comprising a sequence of (a); or

(c) a naturally-occurring polynucleotide having

15

at least 70% identity with a naturally-occurring polynucleotide of (b) and, in naturally-occurring neural cells, has its expression modulated when the cells are subjected to neurotoxic stress;

(d) a naturally-occurring polynucleotide

20

capable of hybridizing under moderately stringent conditions to a naturally-occurring polynucleotide of (b) and, in naturally-occurring neural cells, has its expression modulated when the cells are subjected to neurotoxic stress;

(e) a fragment of a polynucleotide of (a), (b),

(c) or (d) having at least 20 nucleotides; or

25

(f) a polynucleotide sequence complementary to

a polynucleotide of (a), (b), (c), (d) or (e).

30

3. The isolated polynucleotide of claim 2, the expression of which is modulated in neural cells subjected to neurotoxic stress having the sequence of:

(a) any one of SEQ ID NOS: 1-48, 52-64, 66, 68-

84, 86, 88-93, 101-131;

- (b) a naturally-occurring polynucleotide  
comprising a sequence of (a); or
- (c) a naturally-occurring polynucleotide having  
at least 70% identity with a naturally-occurring  
5 polynucleotide of (b) and, in naturally-occurring neural  
cells, has its expression modulated when the cells are  
subjected to neurotoxic stress;
- (d) a naturally-occurring polynucleotide  
capable of hybridizing under moderately stringent conditions  
10 to a naturally-occurring polynucleotide of (b) and, in  
naturally-occurring neural cells, has its expression modulated  
when the cells are subjected to neurotoxic stress;
- (e) a fragment of a polynucleotide of (a), (b),  
(c) or (d) having at least 20 nucleotides; or
- 15 (f) a polynucleotide sequence complementary to  
a polynucleotide of (a), (b), (c), (d) or (e).

4. The isolated polynucleotide of claim 2 the expression of  
20 which is modulated in neural cells subjected to neurotoxic  
stress having the sequence of:

- (a) any one of SEQ ID NOs: 49-51, 65, 67, 85,  
87, 94-100;
- (b) a naturally-occurring polynucleotide  
25 comprising a sequence of (a); or
- (c) a naturally-occurring polynucleotide having  
at least 70% identity with a naturally-occurring  
polynucleotide of (b) and, in naturally-occurring neural  
cells, has its expression modulated when the cells are  
30 subjected to neurotoxic stress;
- (d) a naturally-occurring polynucleotide  
capable of hybridizing under moderately stringent conditions  
to a naturally-occurring polynucleotide of (b) and, in

naturally-occurring neural cells, has its expression modulated  
when the cells are subjected to neurotoxic stress;

(e) a fragment of a polynucleotide of (a), (b),

(c) or (d) having at least 20 nucleotides; or

5 (f) a polynucleotide sequence complementary to

a polynucleotide of (a), (b), (c), (d) or (e).

5. The isolated polynucleotide in accordance with claim 2  
comprising a strand of a full-length cDNA.

10 6. The isolated polynucleotide in accordance with claim 3  
comprising a strand of a full-length cDNA.

15 7. The isolated polynucleotide in accordance with claim 4  
comprising a strand of a full-length cDNA.

8. An isolated polypeptide the expression of which is  
modulated in neural cells subjected to neurotoxic stress,  
comprising a protein encoded by a full length cDNA in  
20 accordance with claim 5, a variant which has an amino acid  
sequence having at least 70% identity to said protein and  
retains the biological activity thereof, or a fragment of said  
protein or variant which retains the biological activity  
thereof, or a functional derivative or salt of said protein,  
25 variant or fragment.

9. An isolated polypeptide the expression of which is  
modulated in neural cells subjected to neurotoxic stress,  
comprising a protein encoded by a full length cDNA in  
30 accordance with claim 6, a variant which has an amino acid  
sequence having at least 70% identity to said protein and  
retains the biological activity thereof, or a fragment of said  
protein or variant which retains the biological activity

thereof, or a functional derivative or salt of said protein,  
variant or fragment.

10 An isolated polypeptide the expression of which is modulated  
5 in neural cells subjected to neurotoxic stress, comprising a  
protein encoded by a full length cDNA in accordance with claim  
7, a variant which has an amino acid sequence having at least  
70% identity to said protein and retains the biological  
10 activity thereof, or a fragment of said protein or variant  
which retains the biological activity thereof, or a functional  
derivative or salt of said protein, variant or fragment.

11. A molecule which comprises the antigen-binding portion of  
an antibody specific for a protein, variant or fragment in  
15 accordance with claim 8.

12. A molecule which comprises the antigen-binding portion of  
an antibody specific for a protein, variant or fragment in  
20 accordance with claim 10.

13. A method for diagnosing cells which have been subjected  
to a neurotoxic insult, hypoxia and/or ischemia, comprising  
assaying for RNA comprising a sequence of any one of SEQ ID  
25 NOs:1-131 or for the expression product of a gene in which one  
of said sequences is a part, the amount of said RNA or  
expression product as compared to a control indicating the  
likelihood that such cells have been subjected to hypoxia or  
ischemia.

14. The method according to claim 13 for diagnosing cells  
30 which have been subjected to a neurotoxic insult, hypoxia  
and/or ischemia, wherein said RNA comprises a sequence of any  
one of SEQ ID NOs:49, 50, 51, 65, 67, 85, 87, 94-100

15. The method according to claim 14 for diagnosing cells which have been subjected to a neurotoxic insult, hypoxia and/or ischemia, wherein said RNA comprises a sequence of SEQ ID NOs: 65, or 94

5

16. A method of screening for a neuroprotective compound comprising testing the ability of the compound to upregulate or downregulate a gene which is transcribed to an RNA containing a sequence of any of SEQ ID NOs: 1-131.

10

17. The method of claim 16 of screening for a neuroprotective compound comprising testing the ability of the compound to upregulate or downregulate a gene which is transcribed to an RNA containing a sequence of any of SEQ ID NOs: 49, 50, 51, 65, 67, 85, 87 and 94-100.

15

18. The method of claim 17 wherein the compound is capable of downregulating the transcription of SEQ ID No:94 or KIAA0538.

20

19. The method of claim 17 wherein the compound is capable of upregulating the transcription of SEQ ID No:65 or KIAA0284 .

20. A method of identifying a neuroprotective compound comprising testing the ability of the compound to inhibit or enhance the activity of a polypeptide which is encoded by a sequence of any of SEQ ID NOs: 1-131, compared to a control.

25

21. The method of claim 20 of identifying a neuroprotective compound comprising testing the ability of the compound to inhibit or enhance the activity of a polypeptide which is

30

encoded by a sequence of any of SEQ ID NOs: 49, 50, 51, 65,  
67, 85, 87 and 94-100.

5 22. The method of claim 21 wherein the compound is screened  
for the ability to inhibit a  $\text{Ca}^{2+}$  promoted Ras inactivator  
encoded by a member of the KIAA0538 gene family.

10 23. A process for identifying a neuroprotective compound  
which specifically inhibits the polypeptide product of  
KIAA0538 gene which comprises:  
(a) contacting cells expressing DNA encoding the KIAA0538  
gene under conditions permitting expression of the DNA; and  
(b) determining if the compound inhibits the polypeptide as  
compared to a control.

15 24. The process of claim 23 wherein the cells are transfected  
with the KIAA0538 gene.

20 25. The process of claim 23 wherein the cells endogenously  
express the KIAA0538 gene.

26. The process of claim 23 wherein the cells are neuronal  
cells.

25 27. A method of preparing a pharmaceutical composition which  
comprises the steps of:  
(a) obtaining a compound which specifically inhibits the  
activity of the polypeptide product of the KIAA0538 gene; and  
(b) admixing said compound with a pharmaceutically  
30 acceptable carrier.

28. The method of claim 21 wherein the compound is screened for the ability to activate or enhance the activity of a polypeptide encoded by KIAA0284.

5 29. A method for screening for a compound which induces or inhibits apoptosis after exposure of neural cells to a neurotoxic insult, comprising the step of exposing the cells to the test compound and testing the change in expression of any one of the polynucleotides according to claim 2.

10 30. The method according to claim 29 for screening for a compound which induces or inhibits apoptosis after exposure of neural cells to a neurotoxic insult, comprising the step of exposing the cells to the test compound and testing the change  
15 in expression of any one of the polynucleotides according to claim 4.

20 31. The method according to claim 30, which comprises testing the compound for its ability to change the expression of any member of the KIAA0538 gene family.

32. The method according to claim 30, which comprises testing the compound for its ability to change the expression of KIAA0284.

25 33. A method for identifying a compound which induces or inhibits apoptosis after exposure of neural cells to a neurotoxic insult, comprising the step of exposing the cells to the test compound and testing the change in expression of  
30 any one of the polypeptides according to claim 7, as compared to a control.



34. The method of claim 33 for identifying a compound which induces or inhibits apoptosis after exposure of neural cells to a neurotoxic insult, comprising the step of exposing the cells to the test compound and testing the change in activity of any one of the polypeptides according to claim 8, as compared to a control.

35. The method of claim 34 wherein the compound is screened for the ability to inhibit a  $\text{Ca}^{2+}$  promoted Ras inactivator encoded by a member of the KIAA0538 gene family.

36. A method of identifying a compound capable of exerting a neuroprotective effect that ameliorates or diminishes the damage induced by a neurotoxic insult, comprising the step of screening for the ability of the compound to alter the level of expression of a polynucleotide according to claim 2, compared to a control.

37. The method of claim 36 of screening for a compound capable of exerting a neuroprotective effect that ameliorates or diminishes the damage induced by a neurotoxic insult, comprising the step of screening for the ability of the compound to alter the level of expression of a polynucleotide according to claim 4.

38. The method according to claim 37, which comprises testing the compound for its ability to inhibit the expression of any member of the KIAA0538 gene family.

39. A method of identifying a compound capable of exerting a neuroprotective effect that ameliorates or diminishes the



damage induced by a neurotoxic insult, comprising the step of screening for the ability of the compound to alter the activity of any one of the polypeptides according to claim 8, compared to a control.

5

40. A method of identifying a compound capable of exerting a neuroprotective effect that ameliorates or diminishes the damage induced by a neurotoxic insult, comprising the step of screening for the ability of the compound to alter the activity of any one of the polypeptides according to claim 10.

10

41. The method of claim 40 wherein the compound is screened for its ability to inhibit the activity of a  $\text{Ca}^{2+}$  promoted Ras inactivator encoded by a member of the KIAA0538 gene family

15

42. Antisense DNA of a length sufficient to prevent transcription and/or translation of a gene, comprising a sequence which is complementary to a portion of a gene of which a sequence of SEQ ID NO:94 is a part.

20

43. The antisense DNA of claim 42 of a length sufficient to prevent transcription and/or translation of a gene, comprising a sequence which is complementary to a portion of a gene of the KIAA0538 gene family.

25

44. In a method for screening drugs which up-regulate or downregulate a gene, the improvement wherein said gene is a gene which is transcribed to an RNA containing a sequence in accordance with claim 2.

30

45. In a method for screening drugs which up-regulate or downregulate a gene, the improvement wherein said gene is a

gene which is transcribed to an RNA containing a sequence in  
accordance with claim 4.

10024399-1004304